Return to homepagePandemic Pact

Development and mechanistic analysis of novel inhibitors of the dengue virus NS1 protein

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA207620

Grant search

Key facts

  • Disease

    Dengue

  • Start & end year

    2022
    2025

  • Known Financial Commitments (USD)

    $565,016.43

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    N/A

  • Research Location

    Australia

  • Lead Research Institution

    Flinders University

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Mosquito-borne flaviviruses such as dengue virus (DENV) cause significant morbidity and mortality in tropical and sub-tropical areas worldwide. The DENV NS1 protein is critical to multiple aspects of the viral life cycle and DENV pathogenesis, making it an appealing target of future antiviral therapies. In this project we will apply a rational multi-disciplinary approach to identify and mechanistically characterise unique NS1-targeting antiviral drugs and future NS1-related drug targets.